Agent: Third generation cephalosporin showed no clear difference in recurrent UTI after end of therapy compared with other antibiotic (low certainty).
Agent: Third generation cephalosporin may leads to lower persistent symptoms after end of treatment compared with other antibiotic (low certainty).
Oral showed no clear difference in mortality compared with intravenous antibiotic therapy (moderate certainty).
Oral showed no clear difference in treatment failure compared with intravenous antibiotic therapy (moderate certainty).
Oral showed no clear difference in treatment failure ‐ per protocol analysis compared with intravenous antibiotic therapy (moderate certainty).
Oral showed no clear difference in treatment failure not dt modification in update compared with intravenous antibiotic therapy (moderate certainty).
Continuous showed no clear difference in all‐cause mortality compared with intermittent Antibiotic Infusions (moderate certainty).
Continuous showed no clear difference in infection recurrence compared with intermittent Antibiotic Infusions (low certainty).
Continuous showed no clear difference in clinical cure compared with intermittent Antibiotic Infusions (low certainty).
Continuous showed no clear difference in super‐infection compared with intermittent Antibiotic Infusions (low certainty).
Continuous showed no clear difference in serious adverse events compared with intermittent Antibiotic Infusions (low certainty).
Continuous showed no clear difference in withdrawal due to adverse events compared with intermittent Antibiotic Infusions (low certainty).
It is very uncertain whether continuous changes adverse events compared with intermittent Antibiotic Infusions (very low certainty).
It is very uncertain whether single‐dose changes persistent bacteriuria compared with short‐course (3‐7 days) antibiotics (very low certainty).
It is very uncertain whether single‐dose changes recurrence compared with short‐course (3‐7 days) antibiotics (very low certainty).
It is very uncertain whether single‐dose changes re‐infection compared with short‐course (3‐7 days) antibiotics (very low certainty).
It is very uncertain whether single‐dose changes persistent bacteriuria compared with conventional 10‐day antibiotic treatment (very low certainty).
It is very uncertain whether single‐dose changes persistent symptoms compared with conventional 10‐day antibiotic treatment (very low certainty).
It is very uncertain whether single‐dose changes persistent bacteriuria and symptoms compared with conventional 10‐day antibiotic treatment (very low certainty).
It is very uncertain whether single‐dose changes recurrence compared with conventional 10‐day antibiotic treatment (very low certainty).